Results 81 to 90 of about 743 (109)

Effect of brivaracetam on CYP3A activity, measured by oral midazolam.

, 2015
peer reviewedBrivaracetam is a synaptic vesicle protein 2A ligand in phase III development for epilepsy. A phase I, open-label, randomized study was conducted in 42 healthy male participants to assess the effect of brivaracetam on CYP3A activity using ...
Watanabe, Shikiko, Scheen, André, Armel Stockis, Shikiko Watanabe, André J. Scheen, Stockis, Armel   +5 more
core   +1 more source

Treatment with brivaracetam has no apparent long‐term effects on body weight in pediatric patients with epilepsy

Epilepsia Open
Objective The objective of this study is to evaluate possible long‐term effects of treatment with brivaracetam (BRV) on body weight in children with epilepsy. Method Post hoc analysis of data from patients (aged 1 month to
Florin I. Floricel, Paula E. Reichel, Najla Dickson, Sofia Fleyshman, Christoph Reichel, Jan‐Peer Elshoff   +5 more
doaj   +1 more source

Cost-effectiveness of cenobamate as a therapeutic alternative for the treatment of focal epilepsy in adults with inadequate seizure control

Global & Regional Health Technology Assessment
Introduction: This study assesses the cost-effectiveness of cenobamate relative to brivaracetam, lacosamide, eslicarbazepine acetate, and perampanel in the management of focal onset seizures (FOS). The objective is to determine whether cenobamate offers
Martina Paoletti, Angela Ragonese, Luca Budassi, Andrea Marcellusi   +3 more
doaj   +1 more source

Brivaracetam Effectiveness and Patient-Reported Outcomes in Clinical Practice: Data From a 12-Month Prospective, Observational Study in the United States. [PDF]

OBJECTIVE: Evaluate real-world effectiveness, patient-reported outcomes (PROs), and safety/tolerability of brivaracetam in patients (≥16 years) with focal-onset seizures currently receiving ≥ 1 antiseizure medication (ASM), and with historical or current
Henninger, Heidi, Sperling, Michael R., French, Jacqueline A., Dongre, Prashant, Elmoufti, Sami, Altalib, Hamada Hamid, Gelfand, Michael, Martin, Melinda S., Dave, Hina, Porter, Roger J., Schulz, Anne-Liv   +10 more
core   +2 more sources

Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond [PDF]

Background Antiseizure medications remain the cornerstone of treatment for epilepsy, although a proportion of individuals with the condition will continue to experience seizures despite appropriate therapy.
Ferlazzo E., La Neve A., Meletti S., Labate A., Chiesa V., Di Bonaventura C., Lattanzi S., Di Gennaro G., Le Piane, E, Di Gennaro, Giancarlo, Di Gennaro, G, Meletti, Stefano, Didato, G, Audenino, D, Pulitano, P, Lattanzi, S, Panebianco, M, Renna, R, Ranzato, F, Consensus Collaborators Group, Coletti Moja, M, Puligheddu Monica, Piccioli, M, La Neve, Angela, Rosati, E, Chiesa, Valentina, Di Bonaventura, Carlo, Pignatta, P, Dainese, F, Cumbo, E, Boero, G, Fallica, E, Cianci, V, La Neve, A, Labate, A, Labate, Angelo, Meletti, S, Puligheddu, M, Di Bonaventura, C, Ferlazzo, E, Lattanzi, Simona, Vergine, S, Ferlazzo, Edoardo, Chiesa, V, Giordano, A   +44 more
core   +1 more source

Intravenous push administration of anti-seizure medications

Frontiers in Neurology
Intravenous push (IVP) administration of anti-seizure medications is becoming increasingly popular among emergency departments. IVP administration eliminates the need for compounding and preparation by the pharmacy department, as well as the need to ...
Raniah Aljadeed, Raniah Aljadeed, Brian W. Gilbert, Tallib Karaze, Megan A. Rech   +4 more
doaj   +1 more source

Analytical method development, validation for the estimation of brivaracetam in bulk drug substance by RP-HPLC and identification of its major degradation product: a quality by design approach

Future Journal of Pharmaceutical Sciences
Background The research involved a systematic and proactive approach, integrating quality considerations throughout the product lifecycle, from initial conception to final production.
Sandip Kumar Dey, Koustav Dutta, Sumanta Mondal, Sagar Suman Panda, Prasenjit Mondal   +4 more
doaj   +1 more source

Erfaringer med et nytt antiepileptikum, brivaracetam, i behandling av pasienter med refraktær epilepsi - En ett års åpen oppfølgingsstudie med fokus på effekt, tolerabilitet og sammenheng med farmakokinetisk variasjon [PDF]

, 2018
Bakgrunn: Epilepsi er en belastende tilstand som medfører dårlig livskvalitet for pasienten og en stor belastning for samfunnet. Omtrent 30 % av pasientene med epilepsi er behandlingsresistente, og det tilstrebes å finne nye og bedre ...
Linge, Hanna Lande
core  

Evaluation of the effectiveness of Brivaracetam in the treatment of status epilepticus: an observational study aimed at defining the optimal dosage.

reservedIntroduzione: Lo stato epilettico (SE) è un’emergenza neurologica gravata da elevata morbilità e mortalità, che frequentemente evolve in forme refrattarie (R-SE) o super-refrattarie (S-RSE). Il Brivaracetam (BRV), ligando ad alta affinità per
PUGLIA, GIULIO
core  

Recognition of antiepileptic brivaracetam by synaptic vesicle protein 2A

Cell Discovery
Shujin Liu, Yulin Chao, Zixuan Zhou, Chuanhui Yang, Zhini Zhu, Yuwei Wang, Qianhui Qu   +6 more
doaj   +1 more source